☆ 4.5 Article

Colorectal Cancer Screening, Version 1.2015 Featured Updates to the NCCN Guidelines

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2015)

获取全文
添加到收藏夹

期刊

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
卷 13, 期 8, 页码 959-968

出版社

HARBORSIDE PRESS
DOI: 10.6004/jnccn.2015.0116

关键词

-

类别

Oncology

资金

  1. Eisai
  2. Bristol-Myers Squibb
  3. Genentech BioOncology
  4. Merck
  5. Novartis Oncology
  6. Novocure
  7. Boehringer Ingelheim Pharmaceuticals, Inc.

向作者/读者索取更多资源

Protocol

社区支持

Reagent

社区支持

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Colorectal Cancer Screening provide recommendations for selecting individuals for colorectal cancer screening, and for evaluation and follow-up of colon polyps. These NCCN Guidelines Insights summarize major discussion points of the 2015 NCCN Colorectal Cancer Screening panel meeting. Major discussion topics this year were the state of evidence for CT colonography and stool DNA testing, bowel preparation procedures for colonoscopy, and guidelines for patients with a positive family history of colorectal cancer.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

Surgery for Hereditary Diffuse Gastric Cancer: Long-Term Outcomes

Joseph D. Forrester, Deshka Foster, James M. Ford, Teri A. Longacre, Uri Ladabaum, Sara Fry, Jeffrey A. Norton

Summary: This study reports the long-term outcomes of total gastrectomy for patients with a family history of gastric cancer and CDH1 gene mutations that predispose to hereditary diffuse gastric cancer (HDGC). The results show that total gastrectomy is recommended for patients with inherited CDH1 mutations and the long-term quality of life following the surgery is acceptable.

CANCERS (2022)

添加到收藏夹
Editorial Material Biochemical Research Methods

MITI minimum information guidelines for highly multiplexed tissue images

Denis Schapiro, Clarence Yapp, Artem Sokolov, Sheila M. Reynolds, Yu-An Chen, Damir Sudar, Yubin Xie, Jeremy Muhlich, Raquel Arias-Camison, Sarah Arena, Adam J. Taylor, Milen Nikolov, Madison Tyler, Jia-Ren Lin, Erik A. Burlingame, Young H. Chang, Samouil L. Farhi, Vesteinn Thorsson, Nithya Venkatamohan, Julia L. Drewes, Dana Pe'er, David A. Gutman, Markus D. Herrmann, Nils Gehlenborg, Peter Bankhead, Joseph T. Roland, John M. Herndon, Michael P. Snyder, Michael Angelo, Garry Nolan, Jason R. Swedlow, Nikolaus Schultz, Daniel T. Merrick, Sarah A. Mazzili, Ethan Cerami, Scott J. Rodig, Sandro Santagata, Peter K. Sorger

Summary: The imminent release of tissue atlases combining multichannel microscopy with single-cell sequencing and other omics data from normal and diseased specimens calls for data and metadata standards to guide data deposition, curation and release. The Minimum Information about Highly Multiplexed Tissue Imaging (MITI) standard, derived from best practices in genomics and microscopy, is introduced for highly multiplexed tissue images and traditional histology.

NATURE METHODS (2022)

添加到收藏夹
Article Oncology

Somatic tumor testing implications for Lynch syndrome germline genetic testing

Kathleen Barrus, Natasha Purington, Nicolette Chun, Uri Ladabaum, James M. Ford

Summary: In cancer treatment, somatic tumor sequencing is commonly used to tailor therapy, but it can also identify patients with germline pathogenic variants causing cancer predisposition syndromes like Lynch syndrome. However, clinicians seem to be unaware of this implication and fail to refer a significant proportion of these patients for genetic testing.

CANCER GENETICS (2022)

添加到收藏夹
Editorial Material Oncology

A Novel Framework for the Next Generation of Precision Oncology Targets

Christopher T. Chen, James M. Ford

JAMA ONCOLOGY (2022)

添加到收藏夹
Article Oncology

Personalised Risk Prediction in Hereditary Breast and Ovarian Cancer: A Protocol for a Multi-Centre Randomised Controlled Trial

Stephanie Archer, Nichola Fennell, Ellen Colvin, Rozelle Laquindanum, Meredith Mills, Romy Dennis, Francisca Stutzin Donoso, Rochelle Gold, Alice Fan, Kate Downes, James Ford, Antonis C. Antoniou, Allison W. Kurian, D. Gareth Evans, Marc Tischkowitz

Summary: This study aims to test the effectiveness of personalized risk estimates in supporting women's mental health and choices about their clinical care. It also evaluates the acceptability, feasibility, and cost-effectiveness of using personalized risk estimates in clinical care.

CANCERS (2022)

添加到收藏夹
Article Biochemistry & Molecular Biology

Enhancing Repair of Oxidative DNA Damage with Small-Molecule Activators of MTH1

Yujeong Lee, Yoshiyuki Onishi, Lisa McPherson, Anna M. Kietrys, Marian Hebenbrock, Yong Woong Jun, Ishani Das, Shanthi Adimoolam, Debin Ji, Michael G. Mohsen, James M. Ford, Eric T. Kool

Summary: Impaired DNA repair activity is associated with increased cancer rates. This study found that certain tyrosine kinase inhibitors, such as nilotinib, can activate the repair enzyme MTH1, which cleanses oxidatively damaged nucleotides. Structural optimization resulted in compounds that strongly activate MTH1 and decrease mutagenic nucleotides in cellular DNA. These findings suggest that MTH1 activators may be a promising strategy to suppress tumorigenesis in individuals with elevated cancer risks.

ACS CHEMICAL BIOLOGY (2022)

添加到收藏夹
Article Oncology

Patient Understanding of Tumor Genomic Testing: A Quality Improvement Effort

Leigha Senter, Deloris Veney, Taylor Surplus, Marcy Haynam, Elizabeth J. Adams, Heather Hampel, Amanda E. Toland, Carolyn J. Presley, Tasleem J. Padamsee, Clara N. Lee, Shelly R. Hovick, Daniel G. Stover

Summary: Tumor genomic testing (TGT) is an important part of cancer care, but many patients have limited understanding of genomics and are not informed about potential incidental germline findings. A PDSA approach is being used to assess and improve patient education before TGT, including reviewing guidelines, conducting focus groups and interviews, and creating a patient-directed animated video.

JCO ONCOLOGY PRACTICE (2023)

添加到收藏夹
Article Oncology

National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice

Funda Meric-Bernstam, James M. Ford, Peter J. O'Dwyer, Geoffrey I. Shapiro, Lisa M. McShane, Boris Freidlin, Roisin E. O'Cearbhaill, Suzanne George, Julia Glade-Bender, Gary H. Lyman, James Tricoli, David Patton, Stanley R. Hamilton, Robert J. Gray, Douglas S. Hawkins, Bhanumati Ramineni, Keith T. Flaherty, Petros Grivas, Timothy A. Yap, Jordan Berlin, James H. Doroshow, Lyndsay N. Harris, Jeffrey A. Moscow

Summary: In the past decade, there have been multiple trials to determine the effectiveness of treating cancer based on specific genomic alterations. However, most patients do not respond to single-agent therapies targeting a single alteration, and drug resistance often develops. To address this, the NCI has developed NCI-ComboMATCH, a study to explore genomically-directed combination therapies and overcome drug resistance.

CLINICAL CANCER RESEARCH (2023)

添加到收藏夹
Review Neurosciences

The foundation and architecture of precision medicine in neurology and psychiatry

Harald Hampel, Peng Gao, Jeffrey Cummings, Nicola Toschi, Paul M. Thompson, Yan Hu, Min Cho, Andrea Vergallo

Summary: Neurological and psychiatric diseases are highly genetically and patho-physiologically heterogeneous. Precision medicine (PM) offers an alternative approach to traditional medical paradigms, focusing on the underlying biology of diseases. This article proposes a PM architecture for central nervous system diseases, based on multimodal biomarkers, systems medicine, digital health technologies, and data science. Alzheimer's disease is discussed as an example, showcasing its potential for PM-oriented neuroscience drug development and advanced healthcare practice.

TRENDS IN NEUROSCIENCES (2023)

添加到收藏夹
Article Genetics & Heredity

Clinical implications of conflicting variant interpretations in the cancer genetics clinic

Elyssa Zukin, Julie O. Culver, Yuxi Liu, Yunqi Yang, Charite N. Ricker, Rachel Hodan, Duveen Sturgeon, Kerry Kingham, Nicolette M. Chun, Courtney Rowe-Teeter, Kathryn Singh, Jason A. Zell, Uri Ladabaum, Kevin J. McDonnell, James M. Ford, Giovanni Parmigiani, Danielle Braun, Allison W. Kurian, Stephen B. Gruber, Gregory E. Idos

Summary: The clinical impact of conflicting classifications of genetic variants issued by commercial laboratories was studied. Results from 2000 patients undergoing genetic testing were analyzed, and discrepancies between laboratory-provided classifications and other laboratories were identified. Only 36% of patients with conflicting classifications had a documented discussion by a provider. The study highlights the frequency of interpretation discrepancies and the importance of clinician awareness.

GENETICS IN MEDICINE (2023)

添加到收藏夹
Article Multidisciplinary Sciences

Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers

James J. Harding, Sarina A. Piha-Paul, Ronak H. H. Shah, Jessica J. Murphy, James M. Cleary, Geoffrey I. Shapiro, David I. Quinn, Irene Brana, Victor Moreno, Mitesh Borad, Sherene Loi, Iben Spanggaard, Haeseong Park, James M. Ford, Monica Arnedos, Salomon M. Stemmer, Christelle de la Fouchardiere, Christos Fountzilas, Jie Zhang, Daniel DiPrimeo, Casey Savin, S. Duygu Selcuklu, Michael F. Berger, Lisa D. Eli, Funda Meric-Bernstam, Komal Jhaveri, David B. Solit, Ghassan K. Abou-Alfa

Summary: In patients with biliary tract cancer, HER2 alterations correlate with poor prognosis. A phase II clinical trial showed that the tyrosine kinase inhibitor neratinib has some efficacy in treating advanced biliary tract cancers with HER2-mutation positive. The objective response rate to neratinib was 16% (95% CI 4.5-36.1%).

NATURE COMMUNICATIONS (2023)

添加到收藏夹
Article Clinical Neurology

The amyloid-β pathway in Alzheimer's disease: a plain language summary

Harald Hampel, Yan Hu, John Hardy, Kaj Blennow, Christopher Chen, George Perry, Seung Hyun Kim, Victor L. Villemagne, Paul Aisen, Michele Vendruscolo, Takeshi Iwatsubo, Colin L. Masters, Min Cho, Lars Lannfelt, Jeffrey L. Cummings, Andrea Vergallo

Summary: This summary reviews the evidence supporting the role of the amyloid-b (Ab) pathway in Alzheimer's disease (AD) and emphasizes the importance of targeting this pathway in early stages of the disease. Understanding and targeting the A beta pathway can lead to better therapeutic outcomes and management of AD.

NEURODEGENERATIVE DISEASE MANAGEMENT (2023)

添加到收藏夹
Article Oncology

Identifying homologous recombination deficiency in breast cancer: genomic instability score distributions differ among breast cancer subtypes

Lauren Lenz, Chris Neff, Cara Solimeno, Elizabeth S. Cogan, Vandana G. Abramson, Judy C. Boughey, Carla Falkson, Matthew P. Goetz, James M. Ford, William J. Gradishar, Rachel C. Jankowitz, Virginia G. Kaklamani, P. Kelly Marcom, Andrea L. Richardson, Anna Maria Storniolo, Nadine M. M. Tung, Shaveta Vinayak, Darren R. Hodgson, Zhongwu Lai, Simon Dearden, Bryan T. Hennessy, Erica L. Mayer, Gordon B. Mills, Thomas P. Slavin, Alexander Gutin, Roisin M. Connolly, Melinda L. Telli, Vered Stearns, Jerry S. Lanchbury, Kirsten M. Timms

Summary: This study evaluated whether the genomic instability score (GIS) distributions of BRCA1/2-deficient estrogen receptor-positive breast cancer (ER + BC) and triple-negative breast cancer (TNBC) are similar to that of ovarian cancer. The results showed that the GIS distribution of BRCA1/2-deficient samples was lower in ER + BC compared to ovarian cancer, but there was no significant difference in TNBC. In TNBC patients, the GIS thresholds were validated using clinical response data to platinum therapy.

BREAST CANCER RESEARCH AND TREATMENT (2023)

添加到收藏夹
Meeting Abstract Oncology

Personalised risk prediction in hereditary breast and ovarian cancer: A protocol for a multi-centre randomised controlled trial

Nichola Fennell, Ellen Colvin, Rozelle Laquindanum, Meredith Mills, Romy Dennis, Francisca Stutzin Donoso, R. Gold, Alice Fan, Kate Downes, James Ford, Antonis Antoniou, Allison Kurian, Gareth Evans, Marc Tischkowitz, Stephanie Archer

PSYCHO-ONCOLOGY (2022)

添加到收藏夹
Article Oncology

Phase II Study of Taselisib in PIK3CA-Mutated Solid Tumors Other Than Breast and Squamous Lung Cancer: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol I

Ian E. Krop, Opeyemi A. Jegede, Juneko E. Grilley-Olson, Josh D. Lauring, Edith P. Mitchell, James A. Zwiebel, Robert J. Gray, Victoria Wang, Lisa M. McShane, Larry Rubinstein, David Patton, P. Mickey Williams, Stanley R. Hamilton, Scott A. Kono, James M. Ford, Agustin A. Garcia, Xingwei D. Sui, Robert D. Siegel, Brian M. Slomovitz, Barbara A. Conley, Carlos L. Arteaga, Lyndsay N. Harris, Peter J. O'Dwyer, Alice P. Chen, Keith T. Flaherty

Summary: The study found that Taselisib monotherapy had limited activity in heavily pretreated cancer patients with PIK3CA-mutated tumors. The presence of a PIK3CA mutation alone does not appear to be a sufficient predictor of Taselisib activity.

JCO PRECISION ONCOLOGY (2022)

添加到收藏夹
暂无数据
研讨会 海报 问题 讨论圈 基金 期刊 论文 科研社交 资讯集成 审稿人 关于我们 常见问题 移动App 隐私条款 使用条款
© Peeref 2019-2024. All rights reserved.